The role of new targeted therapies in small-cell lung cancer.
Lung cancer is the leading world-wide cause of cancer death. Small-cell lung cancer (SCLC) accounts for 20-25% of lung carcinomas. Chemotherapy is the cornerstone of treatment of SCLC. In limited disease, median survival is about 12-16 months with 4-5% of long-term survivors, in extensive disease median survival is 7-11 months. Improving the survival rate of patients with SCLC requires a better understanding of tumour biology and the subsequent development of novel therapeutic strategies. Several targeted agents have been introduced into clinical trials in SCLC and some phase III studies have already produced definitive results. Currently, the minority of these new agents offers a promise of improved outcomes, and negative results are more commonly reported than positive ones. To date, no targeted therapy has been approved for use in the treatment of patients with SCLC. This review will focus on the main novel biologic agents investigated in the treatment of SCLC.
Rossi
A
A
Unità Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, 83100-Avellino, Italy.
Maione
P
P
Colantuoni
G
G
Guerriero
C
C
Gridelli
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000098:blood supply / Q000235:genetics / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D006801:Humans; D016233:Immunotherapy, Active; D008175:Lung Neoplasms / Q000098:blood supply / Q000235:genetics / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D020320:Oligoribonucleotides, Antisense / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D020320:Oligoribonucleotides, Antisense